Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience
In: British Journal of Haematology, Jg. 186 (2019-05-15), S. 561-564
Online
unknown
Zugriff:
Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
Titel: |
Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience
|
---|---|
Autor/in / Beteiligte Person: | Francis, Yvonne ; Desterro, Joana M. P. ; Woodley, Claire ; Alimam, Samah ; Radia, Deepti ; McLornan, Donal P. ; Harrison, Claire ; Kordasti, Shahram ; O'Sullivan, Jennifer ; Natalia Curto Garcia ; Keohane, Clodagh |
Link: | |
Zeitschrift: | British Journal of Haematology, Jg. 186 (2019-05-15), S. 561-564 |
Veröffentlichung: | Wiley, 2019 |
Medientyp: | unknown |
ISSN: | 1365-2141 (print) ; 0007-1048 (print) |
DOI: | 10.1111/bjh.15968 |
Schlagwort: |
|
Sonstiges: |
|